Cryptococcal Antigenemia in Anti-Retroviral Naïve AIDS Patients: Prevalence and Its Association with CD4 Cell Count

  • Oghomwen Favour Osazuwa Mail Department of Medical Microbiology, University of Benin Teaching hospital, PMB 1111.Benin City, Nigeria. AND Federal capital territory administration, Medical microbiology /PEPFAR laboratory, Wuse district hospital, PMB 24, Abuja, Nigeria.
  • Osilume Dirisu Department of Medical Microbiology, University of Benin Teaching hospital, PMB 1111.Benin City, Nigeria. AND Lahor medical research laboratory, Iwogban, Benin City, Nigeria.
  • Evbaguehita Okuonghae Department of Medical Microbiology, University of Benin Teaching hospital, PMB 1111.Benin City, Nigeria.
Cryptococcal antigen, ART-naïve AIDS patients, Sero-prevalence, CD4 counts


Cryptococcus neoformans is the most incriminated fungal pathogen causing meningitis in acquired immune deficiency syndrome (AIDS) patients, and is known to constitute a major cause of deaths in AIDS patients. This study aimed to determine the sero-prevalence and effect of CD4 count on seropositivity for Cryptococcus neoformans antigen (crag) in antiretroviral- naïve (ART-naïve) AIDS patients. This study included 150 (61 males and 89 females) ART-naïve AIDS patients attending the Human Immunodeficiency Virus (HIV) clinic of the University of Benin teaching hospital, Benin City, Nigeria within the period February 2011- July 2011. 40 (18 males and 22 females) HIV positive outpatients with CD4 counts >200 cells/µl who are ART-naive were recruited and used as controls. The prevalence of crag in the patients and control group was determined using the cryptococcal antigen latex agglutination system (CALAS) (Meridian Bioscience, Europe) and CD4 counts were measured using flow cytometry (Partec flow cytometer, Germany). Of 150 ART-naïve AIDS patients with CD4 counts ≤ 200 cells/µL, 19 (12.7%) were positive for serum Cryptococcal antigen. ART-naïve AIDS patients with CD4 count ≤50 cells/µl had the highest prevalence of serum crag. Lower CD4 counts were significantly associated with positivity for serum crag (P<0.001). Age and Sex had no significant effect on the sero-positivity for serum crag. 1 (2.5%) of the control was sero-positive for crag. Serum crag was significantly associated with AIDS but not with HIV (P<0.001). This study uncovers a high prevalence of crag in ART-naïve AIDS patients in Benin City. There is an urgent need to introduce early and routine screening for crag in ART-naïve AIDS patients for prompt intervention.


Okongo M, Morgan D, Mayanja B, Ross A, Whitworth J. Causes of death in a rural, population-based human immunodeficiency virus type 1 (HIV-1) natural history cohort in Uganda. Int J Epidemiol 1998;27(4):698-702.

Bicanic T, Meintjes G, Rebe K, Williams A, Loyse A, Wood R, Hayes M, Jaffar S, Harrison T. Immune reconstitution inflammatory syndrome in HIV-associatedcryptococcal meningitis: a prospective study. J Acquir Immune Defic Syndr 2009;51(2):130-4.

van der Horst CM, Saag MS, Cloud GA, Hamill RJ, Graybill JR, Sobel JD, Johnson PC, Tuazon CU, Kerkering T, Moskovitz BL, Powderly WG, Dismukes WE. Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Instituteof Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group. N Engl J Med 1997;337(1):15-21.

Michaels SH, Clark R, Kissinger P. Incidence and spectrum of AIDS-defining illnesses among persons treated with antiretroviral drugs. Clin Infect Dis 1999;29(2):468-9.

Benson CA, Kaplan JE, Masur H, Pau A, Holmes KK; CDC; National Institutes of Health; Infectious Diseases Society of America. Treating opportunistic infections among HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association/Infectious Diseases Society of America. MMWR Recomm Rep 2004;53(RR-15):1-112.

Pinner RW, Hajjeh RA, Powderly WG. Prospects for preventing cryptococcosis in persons infected with human immunodeficiency virus. Clin Infect Dis 1995;21 Supplm1:S103-7.

Cameron ML, Bartlett JA, Gallis HA, Waskin HA. Manifestations of pulmonary cryptococcosis in patients with acquired immunodeficiency syndrome. Rev Infect Dis 1991;13(1):64-7.

Aberg JA, Watson J, Segal M, Chang LW. Clinical utility of monitoring serum cryptococcal antigen (sCRAG) titers in patients with AIDS-related cryptococcal disease. HIV Clin Trials 2000;1(1):1-6.

Skiest DJ, Hester LJ, Hardy RD. Cryptococcal immune reconstitution inflammatory syndrome: report of four cases in three patients and review of the literature. J Infect 2005;51(5):e289-97.

Desmet P, Kayembe KD, De Vroey C. The value of cryptococcal serum antigen screening among HIVpositive/ AIDS patients in Kinshasa, Zaire. AIDS 1989;3(2):77-8.

Liechty CA, Solberg P, Were W, Ekwaru JP, Ransom RL, Weidle PJ, Downing R, Coutinho A, Mermin J. Asymptomatic serum cryptococcal antigenemia and early mortality during antiretroviral therapy in rural Uganda. Trop Med Int Health 2007;12(8):929-35.

Meya DB, Manabe YC, Castelnuovo B, Cook BA, Elbireer AM, Kambugu A, Kamya MR, Bohjanen PR, Boulware DR. Cost-effectiveness of serum cryptococcal antigen screening to prevent deaths among HIV-infected persons with a CD4+ cell count < or = 100 cells/microL who start HIV therapy in resource-limited settings. Clin Infect Dis 2010;51(4):448-55.

Jarvis JN, Lawn SD, Vogt M, Bangani N, Wood R, Harrison TS. Screening for cryptococcal antigenemia in patients accessing an antiretroviral treatment program in South Africa. Clin Infect Dis 2009;48(7):856-62.

Pongsai P, Atamasirikul K, Sungkanuparph S. The role of serum cryptococcal antigen screening for the early diagnosis of cryptococcosis in HIV-infected patients with different ranges of CD4 cell counts. J Infect 2010;60(6):474-7.

Micol R, Lortholary O, Sar B, Laureillard D, Ngeth C, Dousset JP, Chanroeun H, Ferradini L, Guerin PJ, Dromer F, Fontanet A. Prevalence, determinants of positivity, and clinical utility of cryptococcal antigenemia in Cambodian HIV-infected patients. J Acquir Immune Defic Syndr 2007;45(5):555-9.

Aluyi HAS, Otajevwo FD, Iweriebor O. Incidence of pulmonary mycoses in patients with acquired immunedeficiency diseases. Nig J Clin Pract 2010;13(1):78-83.

Lara-Peredo O, Cuevas LE, French N, Bailey JW, Smith DH. Cryptococcal infection in an HIV-positive Ugandan population. J Infect 2000;41(2):195.

Kisenge PR, Hawkins AT, Maro VP, McHele JP, Swai NS, Mueller A, Houpt ER. Low CD4 count plus coma predicts cryptococcal meningitis in Tanzania. BMC Infect Dis 2007;7:39.

Jarvis JN, Meintjes G, Harrison TS. Outcomes of cryptococcal meningitis in antiretroviral naïve and experienced patients in South Africa. J Infect 2010;60(6):496-8.

Currie BP, Casadevall A. Estimation of the prevalence of cryptococcal infection among patients infected with the human immunodeficiency virus in New York City. Clin Infect Dis 1994;19(6):1029-33.

How to Cite
Osazuwa OF, Dirisu O, Okuonghae E. Cryptococcal Antigenemia in Anti-Retroviral Naïve AIDS Patients: Prevalence and Its Association with CD4 Cell Count. Acta Med Iran. 50(5):344-347.